These White House deals will require the nine midsize pharma companies to provide MFN prices to state Medicaid programmes nationally.

Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease drug developer Merida Biosciences. The deal for Merida, wh ...

The US FDA has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).

The Australia-based STAREE trial is the first of its kind demonstrating the preventative effects of statins in older patients.

The myasthenia gravis (MG) market across the 7MM is poised to grow at a CAGR of 11.1% from $4.5bn in 2024 to $13.0bn in 2034.

The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.

Priovant is now looking to roll out Lisraya, the first targeted therapy for dermatomyositis, across the US via specialty pharmacies.

Armed with oral administration and a cheaper price tag, Lipfendra is touted as a major advancement for patients.

AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B.

K-911 is being developed as a topical ophthalmic monotherapy formulated as a sterile solution. Credit: Gorodenkoff / Shutterstock.com. The US Food and Drug Administration (FDA) is set to review Kowa ...

Study shows that those with low adherence of blood pressure-lowering drugs had significantly impaired therapeutic effect.